Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine

Journal of Infectious Diseases

Volumn 192, Issue 11, 2005, Pages 1962-1965

  Marks, Florian ^a   Von Kalckreuth, Vera ^a   Kobbe, Robin ^a   Adjei, Samuel ^a,b   Adjei, Ohene ^b   Horstmann, Rolf D ^a   Meyer, Christian G ^a   May, Jürgen ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

FANSIDAR; PLACEBO; PYRIMETHAMINE;

ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRUG RESISTANCE; FEMALE; GENE MUTATION; HUMAN; INFANT; INFECTION RATE; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; PARASITOLOGY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; RISK ASSESSMENT;

ANIMALS; ANTIMALARIALS; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; INFANT; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE;

EID: 27944491124     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/497698     Document Type: Article

References (11)

1. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001; 357:1471-7.
2. Schellenberg D, Menendez C, Aponte JJ, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 2005; 365:1481-3.
3. World Health Organization (WHO). A strategic framework for malaria prevention and control during pregnancy in the African region. AFR/MAL/04/01. Brazzaville, Republic of the Congo: WHO, 2004.
4. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxinepyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999; 353:632-6.
5. Kayentao K, Kodio M, Newman RD, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis 2005;191:109-16.
6. Coulibaly D, Diallo DA, Thera MA, et al. Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg 2002; 67:604-10.
7. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993; 87:75-8.
8. May J, Meyer CG. Chemoresistance in falciparum malaria. Trends Parasitol 2003; 19:432-5.
9. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002; 185:380-8.
10. Marks F, Evans J, Meyer CG, et al. High prevalence of markers for sulfadoxine and pyrimethamine resistance of Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana, Antimicrob Agents Chemother 2005;49:1101-5.
11. White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005;2(1):e3.